Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Atomoxetine QoL in ADHD Children and Adolescents
NCT00320528Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Apr 2006
- Primary completion
- Oct 2008
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of atomoxetine in attention deficit hyperactivity disorder (ADHD), sponsored by Eli Lilly and Company. Started Apr 2006; status: completed.
02
Drugs
atomoxetine
03
Conditions
attention deficit hyperactivity disorder (ADHD)
Beyond the preview
Go deeper on NCT00320528.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00320528.